Business Wire

Velodyne Lidar Commends NHTSA Plan to Update NCAP

Share

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.)

NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and blind spot intervention. The proposal asks for comments on how best to develop a NHTSA rating system for ADAS technologies. It also requests comments on potential approaches for conveying this information on the Monroney label, which is displayed on all new automobiles and provides important vehicle information to consumers.

“NHTSA’s proposal has the potential to save lives. Adding ADAS to NCAP is an excellent step forward in advancing safety features in cars and educating consumers on what those features can and cannot do,” said Mircea Gradu, PhD, Senior Vice President of Product and Quality, Velodyne Lidar. “Velodyne has long been engaged with NHTSA and other auto safety leaders on how to standardize ADAS features and establish a rating system that measures ADAS levels of performance. We are eager to work with the agency and all stakeholders on completing this important initiative.”

Velodyne has for years been dedicated to testing lidar sensors and developing safety metrics for ADAS systems. NHTSA’s new plans allow Velodyne to share the company’s findings, weighing in on the capabilities of lidar-centric ADAS systems which have superior performance after sundown, an advantage over current radar+camera-based ADAS solutions. Lidar is self-illuminating; its array of laser beams can accurately perceive the environment in darkness as well as in daylight. Lidar has long been a key sensor for autonomous driving and now Velodyne is applying lidar technology for ADAS vehicle safety, planning to offer software and lidar system solutions in increasing increments of safety and protection.

Five-Diamond ADAS Rating System

Velodyne has a long-standing commitment to fostering understanding of the safety and mobility benefits of advanced driving capabilities to consumer, business, government, public safety and community audiences. These efforts include developing a framework for a five-diamond rating system, aimed at establishing standardized performance assessments of ADAS features. The system is designed to encourage transparency in the marketplace and promote the maximum positive effect of ADAS technologies.

The five-level rating system utilizes diamonds to mark significant milestone achievements in vehicle system performance. The foundational ADAS technologies included in the five-diamond rating system are adaptive cruise control, lane keep assistance, automatic emergency braking, automatic emergency steering and blind spot monitoring.

Velodyne has presented the proposed system to encourage refinement and quantification of the performance descriptors to organizations that include NHTSA, SAE International, Insurance Institute for Highway Safety (IIHS), National Transportation Safety Board (NTSB) and International Alliance for Mobility Testing and Standardization (IAMTS). Velodyne developed a white paper on the rating system, called “An ADAS Feature Rating System: Proposing a New Industry Standard.”

Velodyne envisions the ADAS assessment system results can be incorporated into the Monroney label. Velodyne has developed a proposed ADAS rating label for government and industry review. It is similar to the current NHTSA-developed crash-worthiness label and can be used to educate consumers on vehicle ADAS capabilities before they make car purchases.

Improving ADAS to Reduce Nighttime Dangers to Pedestrians

Velodyne has also called for increased testing of ADAS performance in dark nighttime scenarios. This expansion would address a gap in current testing protocols, which primarily look at daytime conditions and largely overlook the risks to pedestrians from ADAS features that perform poorly in dark nighttime conditions.

Over 6,000 pedestrians are killed every year in traffic-related crashes in the United States with the vast majority of fatalities occurring in dark conditions, per NHTSA reports. Current ADAS, with pedestrian automatic emergency braking (PAEB) that utilizes camera and radar technology, frequently fail to protect pedestrians in dark conditions according to independent testing by NHTSA and the American Automobile Association (AAA).

To reflect real-life conditions, Velodyne proposes expanding PAEB testing protocols to include tests conducted in dark nighttime conditions. This change would protect the public and provide consumers useful information on the capabilities and limitations of different pedestrian detection systems.

This proposal is addressed in a Velodyne white paper, “Improving Pedestrian Automatic Emergency Braking (PAEB) in Dark, Nighttime Conditions.” The white paper also includes the results of nighttime PAEB tests conducted by Velodyne. The tests evaluated a highly-rated PAEB system using camera and radar-based technology and Velodyne’s PAEB system that uses Velodyne’s Velarray H800 sensor and Vella™ software. In these nighttime conditions, the camera and radar-based PAEB system failed in all five scenarios while the lidar-based system avoided a crash in every situation tested.

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

Forward Looking Statements

This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; uncertainties related to Velodyne's estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; Velodyne's ability to identify and integrate acquisitions; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations
Andrew Hamer
Chief Financial Officer
InvestorRelations@velodyne.com

Media
Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye